⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2841707 | 1.00 | — | — | |
| SCHEMBL2377412 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL4650501 | 0.97 | — | — | |
| SCHEMBL1352284 | 0.92 | — | — | |
| SCHEMBL56375 | 0.92 | — | — | |
| SCHEMBL56946 | 0.92 | — | — | |
| SCHEMBL24760387 | 0.89 | GAA (0.33) | — | |
| Methane SCHEMBL7933332 | 0.89 | GAA (0.33) | — | |
| Hydrochloric Acid SCHEMBL4599773 | 0.89 | GAA (0.33) | — | |
| SCHEMBL31438370 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689702-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-30 | — | — | EP | claimed |
| WO-2019158019-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2019-08-22 | — | — | WO | disclosed |
| WO-2013055577-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-1689702-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| EP-2266951-A1 | Organic compounds | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-7851642-B2 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compound | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| US-20090253701-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253703-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-7582782-B2 | 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (1-hydroxymethyl-cyclopentyl)-amide; hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, alzheimers | NOVARTIS AG (CH) | 2009-09-01 | — | — | US | disclosed |
| US-20070135498-A1 | 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (1-hydroxymethyl-cyclopentyl)-amide; hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, alzheimers | NOVARTIS AG (CH) | 2007-06-14 | — | — | US | disclosed |
| EP-1689702-A1 | ORGANIC COMPOUNDS | NOVARTIS-PHARMA GMBH (AT) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051895-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |